New Perfluorophtalate Complexes of Platinum(II) With Chemotherapeutic Potential by de Oliveira, M. B. et al.
NEW PERFLUOROPHTALATE COMPLEXES OF PLATINUM(II)
WITH CHEMOTHERAPEUTIC POTENTIAL
M. B. de Oliveiral,2*, j. Miller2,3,, R. E. Banks4, L. R. Kelland5, C. A. McAuliffe4,
N. Mahmood6, and I. J. Rowland7
Federal University of Paraiba, Department of Chemistry/CCEN, Campus 1,
58059-000, JoAo Pessoa, PB, Brazil
2 Federal University of Minas Gerais, Department of Chemistry/ICEx, Campus of Pampulha,
31270901.Belo Horizonte, MG, Brazil
3 Federal University of Paraiba, Laboratory of Pharmaceutical Technology, Campus 1,
P.O. Box 5009, 58051-970, Joo Pessoa, PB, Brazil
4 University of Manchester Institute of Science and Technology, Department of Chemistry,
P.O.Box 88, Manchester M60 1GD, UK
5 CRC Centre for Cancer Therapeutics, Institute of Cancer Research,
15 Cotswold Rd, Sutton, Surrey SM2 5NG, UK
6 Medical Research Council Collaborative Centre, 1-3 Burtonhole Lane, Mill Hill,
London NW7 lAD, London, UK
7 Institute of Cancer Research, Royal Marsden Hospital, Downs Rd,
Sutton, Surrey SM2 5PT, UK
Abstract
To new platinum(II) complexes have been synthesized and their anti-tumour and anti-HIV activities have
been evaluated.
The new complexes are: (i) cis-tetrafluorophthalate-ammine-morpholine-platinum(II) or MMF3 and (ii) cis-
tetrafluorophthalate-ammine-piperidine-platinum(II or MPF4. They were characterized by elemental analysis,
IR spectra and H and 13C NMR spectra.
They were tested against five human ovarian carcinoma cell lines, viz., CH1, CHlcisR, A2780, A2780cisR
and SKOV-3. They were less active than cis-platin and showed cross-resistance with cis-platin in the
CH1cisR and A2780cisR acquired resistance lines.
They were also tested for possible anti-HIV activity using the HIV-I IIIB virus and C8166 cells, but they
were inactive compared with AZT.
Introduction
The 1969 paper by Rosenberg et al. on the anti-tumoral activity of platinum complexes markedly
increased the interest in metal-based drugs, evidenced by the 1974 review by Cleare2.
Cis-platin (cis-diammine-dichloro-platinum(II) or CDDP) has potent anti-tumour effects not only on
murine tumours such as L1210 leukemia and sarcoma 180(3), but also on various kinds of human tumours
including testicular, ovarian, vaginal cervix, lung, bladder, head and neck tumours.
However, it has serious adverse effects such as nephrotoxicity, nausea and vomiting, which clearly
limit the efficacy of the drug(4). Many analogues of cis-platin have since been synthesized and tested, in
attempts to develop new complexes which may be less toxic and which may have a different spectrum of
activity; including activity against cis-platin resistant lines. One of the first new drugs was cis-diammine-
(1,1-cyclobutanedicarboxylate)platinum (II), or carboplatin. It has similar activity to cis-platin, but is less
toxic. These new analogues were classed as second generation drugs: three of them are shown in Figure 1.
It has been demonstrated recently that CDDP- resistant tumours such as a subline of murine L1210
(6 7) leukemia5 and human cell tumour lines show a high cross-resistance to CBDCA in studies carried out in
vitro.
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Platinum derivatives are among the most active agents for the treatment of several types of cancer.
Prior to the discovery of cis-platin the cure rate in such cases was only 5-10%. However, with current cis-
platin based chemotherapy protocols approximately 80-90% of such patients can expect long-term survival
free of disease. Following cis-platin based therapy, 30% of patients with stage III ovarian cancer can expect
to live for at least 10 years, whereas without it, the survival rate is only about 10%(8’9).
Figure 1. Some Second Generation Platinum Anti-Cancer Drugs
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As part of a search for effective platinum-based drugs with lesser collateral effects,
differences in hydrophilicity and lipophilicity and in reactivity in biological media, with the potential of oral
administration, we have initiated studies with complexes containing organo-fluoro< and mixed amine
ligands
)
lerfluoro-carboxylate ligands should be more labile than corresponding complexes without fluorine,
just as perfluorocarboxylic acids are more acidic than the corresponding acids without fluorine. However the
increase in lability may not be enough to attain that of a chloro ligand. We judge this to be the case for the
tetrafluorophthalate ligands. This might lead to longer life in biological media and increase the chances of
reaching some tumours. Collateral effects may also be ameliorated.
As regards the amine ligands, changes in these may also modify the intrinsic chemotherapeutic
effects as well as altering physical properties and thus distribution of the drug in vivo.
With this background, we have prepared two new perfluorocarboxylate complexes containing one
ammine and also one amino type ligand. They have been tested for anti-cancer and anti-HIV activity.
Results and Discussion
The present work is part of a wider study of potential third generation platinum anti-cancer drugs. The
selection of the new complexes stemmed from the following considerations:
(i) the complexes should be neutral molecules and with configuration cis; (ii) they should contain two
different amine ligands; (iii) they should contain a perfluoro-dicarboxylate type ligand.
This may give them lability between those of carboplatin and cis-platin and greater lipophilicity than either.
The level of lability in biological media may enable them to reach tumours requiring considerable time for
access. They may have greater ability to pass through cell membranes.
(9) It has been suggested for cis-platin that after penetration of the cell membrane the chlorine atoms are
displaced by aquo (or possible hydroxy) ligands; while it is the new complex which interacts more readily
with the nucleophilic centres of nucleotides.
Figure 2 shows the analogous situation with our complexes.
Biological Activity
A) Anti-cancer tests
The tests of compounds MMF3 and MPF4 were carried out at the CRC Centre for Cancer Therapeutics,
Institute of Cancer Research, U.K.
Cell lines: Five human ovarian carcinoma cell lines were used; three "parent" lines CH1, A2780 and
SKOV-3 and two selected for acquired resistance to cis-platin, CHlcisR and A2780cisR. Details of the
establishment and biological properties of these lines have been described previously (12). All lines grew as
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monolayers in Dulbecco’s Modified Eagles’ Medium (DMEM) plus 10% heat inactivated foetal calf serum,
50 tg/ml of gentamycin, 2.5 l.tg/ml of amphotericin B, 2 mM L glutamine, 10 tg/ml insulin and 0.5
M.g/ml of hydrocortisone in 10% CO2/90% air. Cells were routinely checked and found to be free of
Mycoplasma.
Figure 2. Pictorial view of the new complex being delivered to a tumour cell
F F
O Pt"
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Assessment of growth inhibition.
MMF3 and MPF4 were dissolved at 20 mM in DMSO and growth inhibition assessed using the
Sulforhodamine B (SRB) assay as described previously(12). Summarising, cells were seeded into 96-well
microtiter plates at 3000-5000/well in 160 gl of growth medium and allowed to attach overnight. Drugs
were than added at ten different concentrations (100, 25, 10, 2.5, 1, 0.25, 0.1, 0.025, 0.01 and 0.0025 gM)
to quadruplicate wells and left in contact with cells for 96 h. Basic amino acid content per well was then
determined by fixing cells in 10% ice-cold trichloroacetic acid, washing with water, staining with
sulforhodamine B (0.4% in 1% acetic acid) and solubilising with 100 gl of 10 mM Tris base before
determining absorbance values for each well at 540 nm using a plate reader (Titertek multiscan MCC/340).
Growth inhibition was then assessed in terms of IC50 values (50% inhibitory concentration compared to
control untreated cells). Resistance factors (IC50 resistant line/parent line) have been determined for the two
pairs of cell lines.
Results
Table 1: IC5o values (in mM)
ovarian
carcinoma
CH1
CHlci’sR
A2780
A2780cisR
SKOV-3
MMF3
3.4
9.5
RF(2.8)
4.95
47
RF(9.5)
>100
MPF4
7.3
24
RF(3.3)
5.2
42
RF(8.1)
50
Cisplatin
0.1
0.7
RF(7)
0.3
3.6
RF(12)
4.4
Conclusions
Both of the complexes exhibited evidence of in vitro anticancer activity against a panel of five human
ovarian carcinoma cell lines. In comparison with data obtained under the same experimental conditions for
(12-) cis-platin, and reported previously the compounds showed a similar pattern of response to cis-platin but
with less potency. The ICs0 values (/.tM) for cis-platin are included in Table I. MMF3 and MPF4 generally
shared cross-resistance with cis-platin in the two acquired-resistance lines (although resistance factors were a
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little lower than those obtained for cisplatin) and, as with cis-platin, were not particularly potent against the
intrinsically resistant SKOV-3 cell line.
B) Anti-HIV tests
The two complexes were tested against the HIV-I IIIB virus and C8166 cells at the Medical Research Council
Collaborative Centre, U.K. The results are shown in Table 2 and indicate that the complexes are inactive
compared with AZT.
Compound
MPF4 (2) LH
MMF3 LH
AZT
Control
Table 2: Anti-HIV Activity
Conc
(tM)
50
10
2
50
10
2
10
0.016
0.003
0
Syncytia
(+/-)
Con!
+
+
+
+
+
+
+
+
+
Ag
gp120
%of
rol
95
100
86
100
58
100
100
Estimated Cell Growth
% of Control
Infected
11
15
16
14
13
17
101
25
24
19
Uninfected
13
77
98
44
80
95
101
100
ECs0 TCso
>20 20
>50 50
0.016 >100
0
ECs0 represents the concentration which reduces the Ag gpl20 by 50% in infected cell cultures. TCs0
represents the concentration of drug which reduces cell growth by 50%.
Antiviral Assays
The anti-HIV activity and toxicity of compounds were assessed in C8166 cells infected with HIV-I IIIB. The
cells were cultured in RPMI 1640 with 10% calf serum. Aliquots of 4 x 10 cells per microtiter plate well
were mixed with 5-fold dilutions of compounds prior to addition of 10 CCLD0 units of virus and incubated
for 5-6 days. The inhibition of infection was measured by examining Synctia and estimating gp 120 antigen
in the infected culture supernatant by ELISA, using the lectin GNA (from Galanthus nivalis) to capture the
glycoprotein and human anti-HIV serum for detection, as described previouslyC3).
Cell viability of infected and uninfected control cells was measured by the XTF-Formazan methodCl4). The
EC50 is the concentration of compound which reduced the production of gp 120 by 50%. The TCs0 is the
concentration of the compound which reduced the viability of uninfected cells by 50%.
Experimental
Materials and Methods
IR spectra were obtained using KBr pellets on a Perkin-Elmer 247 spectrometer.
Nuclear Magnetic Resonance spectra were obtained on a Bruker AC 300 spectrometer: tH spectra were
obtained in CDC13 at 300 MHz and 3C spectra in CDC13 at 75 MHz.
K2PtCI4 was obtained from Johnson Matthey plc (via UMIST), morpholine and piperidine from the Aldrich
Chemical Co and tetrafluorophthalic acid from Fluorochem Ltd.
Cis-tetrafluorophthalate-ammine-morpholine-plafinum(II) or complex (MMF3) and cis-tetrafluorophthalate-
ammine-piperidine-platinum (II) or complex 2 (MPF4) are new compounds synthesized as potential third
generation drugs.
Their synthesis is outlined in Figure 3.
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Figure 3: Outline Scheme for Synthesis of the Perfluorophthalate Complexes
i) KI O
iii)ii)
Amine (A)
Dicarboxylate O O KPtC14 (a), (b), (c)
F F
Complex 1; X= O
Complex 2; X= CH2
Amine(A) Morpholine, piperidine.
Dicarboxylate Silver tetrafluorophthalate; (a) H20/EtOH;(b HC104 aq./acetone;(c)NH aq.
Complex 1 (MMF3): 1.0 g of K2PtC14 (2.4. mmoles) and 1.6 g of KI (9.6 mmoles) were dissolved in 10
ml of water with stirring. Morpholine (0.42 g; 0.42 ml; 4.8 mmoles) was then added while cooling the
reaction mixture in an ice bath. The intermediate (A), cis-diiodo-dimorpholine-platinum(II) (cis-
[PtIz(C4H9NO)2] precipitated (1.28 g; 2.05 mmoles; 85% yield). It was washed with aqueous ethanol then
dried.The intermediate (A) was dissolved in 10 ml of acetone and 2.9 ml of 2.8 M HC104 aq. solution added
with stirring. The precipitate which formed was washed with acetone to give (B) [Ptlz(C4H9N0)] (1.02 g;
1.1 mmoles; 92% yield). It was dissolved in 10 ml water and 5.7 ml of M NH3 aq. added with stirring.
Intermediate (C) (0.93 g; 1.68 mmoles; 88% yield) cis-diiodo-ammine-morpholine-platinum(II), precipitated.
It was separated, suspended in acetone and 0.3 g (0.64 mmoles) of silver tetrafluorophthalate added with
stirring and this continued overnight at room temperature. The mixture was centrifuged, the AgI filtered off
and washed with water. The washings and the acetone layer were partially evaporated then combined. The
product, MMF3. cis-tetrafluorophthalate-ammine-morpholine-platinum(II) was thus obtained in 97% yield
(0.85 g; 1.64 mmoles) and recrystallized from acetone.
Elemental analysis (%) calculated for intermediate (C), [Pt I2 (C4H9NO)(NH3)]"
C,8.68; H,2.18; N,5.06; 1,45.85; Pt,35.27. Found: C,8.70; H,2.12; N,4.85; 1,45.55; Pt,34.80.
Mp 160C 162C.
The IR spectrum of intermediate (C) showed bands at Vmax(Cm-l) 3000-3100(N-H st); 2860(C-H st); 1470(C-
H def); 1400-1000 (C-N;C-O-C st); 1260(C-O st); 1200-980 (C-H def); 520 (Pt-N st); 290 (Pt-I st).
Elemental analysis (%)calculated for cis-[Pt{C6F4(CO2)2}(C4H9NO)(NH3)], (MMF3):
C,26.93; H,2.26; N,5.23; F,14.20; Pt,36.46. Found: C,25.90; H,2.23, N,4.90; F,13.85; Pt,35.85.
Mp 194C with decomposition.
The IR spectrum of MMF3 showed bands at Vmax(Cm-1) 3400-3000 (N-H St); 2860(C-H st of N-CH2);
1640(C=O st); 1470(C-H def); 1400-1100(C-N st); 1360-1140(C-F st); 1260(C-O st); 1200-1000(C-H def);
520(Pt-N st), coherent with the proposed structure.
1H NMR spectrum (ppm) Ha 1.7(m); Hb 2.9(m); Hc 3.6(m).
3C NMR spectrum (ppm) from perfluorophthalate 167(C1-C8); 131(C2-C7 ); 129(C3-C6) and 132(C4-
C5). From ammine: 47(C-N) and 70 (C-O).
Complex 2 (MPF4): 1.0 g of KPtC14 (2.4 mmoles) and 1.6 g of KI (9.6 mmoles) were dissolved in 10
ml of water with stirring. Piperidine (0.41 g; 0.48 ml; 4.8 mmoles) was then added while cooling the
reaction mixture in an ice bath. The intermediate (A), cis-diiodo-dipiperidine-platinum(II) (cis-[Ptl2(CsHlN)]
precipitated (1.38 g; 2.2 mmoles; 92% yield). It was washed with aqueous ethanol then dried.The
intermediate (A) was dissolved in 10 ml of acetone and 3.1 ml of 2.8 M HC104 aq. solution added with
stirring. The precipitate was washed with acetone to give (B) [PtI2(CsHllN)]n (1.03 g; 1.9 mmoles; 86%
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yield). It was dissolved in 10 ml water and 5.7 ml of M NH aq. added with stirring. Intermediate (C) (0.70
g; 1.2 mmoles; 67% yield) cis-diiodo-ammine-piperidine-platinum(II), precipitated. It was separated,
suspended in acetone and 0.32 g (0.7 mmoles) of silver tetrafluorophthalate added with stirring and this
continued overnight at room temperature. The mixture was centrifuged, the AgI filtered off and washed with
water. The washings and the acetone layer were partially evaporated then combined. The product, MPF4 cis-
tetrafluorophthalate-ammine-piperidine-platinum(II) was thus obtained in 66% yield (0.23 g; 0.4 mmoles)
and recrystallized from acetone.
Elemental analysis (%) calculated for intermediate (C), cis-[PtI2(CsH11N)(NH3)]:
C,10.89; H,2.56; N,5.08; 1,46.06; Pt,35.40. Found: C,11.03; H,3.12; N,4.85; 1,45.85; Pt,36.01.
Mp 160C with decomposition.
The IR spectrum of intermediate (C) showed bands at Vmax(Cm-1) 3400-3000(N-H st); 2930-2860(C-H st);
1600-1470(N-H def.); 1350-1000(C-N,N-H st); 510 (Pt-N st); 300(Pt-I st).
Elemental analysis (%)calculated for cis-[Pt{C6Fn(CO2)2}(CsHllN)(NH3)], (MPF4):
C,29.29; H,2.64; N,5.25; F,14.25; Pt,36.60 Found: C,30.20; H,2.64, N,4.95; F,13.80; Pt,35.98.
Mp 189C 191C.
The IR spectrum of MPF4 showed bands at Vmax(Cm1) 3300-3000(N-H st); 2860(C-H st); 1630(C=O st);
1470(C-H def); 1400-t100(C-N st); 1340-1140(C-F st); 1200-1000(C-H def); 510(Pt-N st), coherent with
the proposed structure.
1H NMR spectrum (ppm): Ha and Hb, 2.8 (m); Hc 1.6 (m).
13C NMR spectrum (ppm): From tetrafluorophthalate 167(C1-C8); 130(C2-C7); 128(C3-C6)and 131(C4-
C5). From ammine: 48(C-N); 34(C*-C-N) and 27(C-C*-C) ppm.
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